This medication is a dual GIP and GLP-1 receptor agonist providing comprehensive metabolic regulation. It enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, leading to effective glycemic control and clinically significant weight loss.
Recommended for:
Clinical evidence:
Tirzepatide has been evaluated in the extensive SURPASS clinical trial program. These randomized, multicenter studies demonstrated superior reductions in HbA1c and body weight compared to insulin glargine and GLP-1 receptor agonists. The drug is approved by the FDA and EMA, confirming its safety and efficacy for long-term use.
The product is used to stabilize blood glucose levels and improve overall metabolic health with consistent weekly administration.
Administered subcutaneously once weekly. One vial contains four doses, providing a complete one-month treatment course. Dosage and initiation should be determined by a healthcare professional. Not intended for intravenous or intramuscular administration.
Contraindications:
Side effects:
